“Regarding Sun Pharma's recent acquisition, Sandip Sabharwal notes a positive initial market reaction and strategic fit, but cautions that large pharma deals require time for integration and the acquisition price appears high, suggesting a watch-and-wait approach for investors.”

Sandip Sabharwal’s track record: 8 graded calls · 95% CI 22–78%